Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other financing activities: 2019-2024

Historic Other financing activities for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $1.6 million.

  • Kymera Therapeutics' Other financing activities fell 34.63% to $419,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 282.96%. This contributed to the annual value of $1.6 million for FY2024, which is 1973.68% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Other financing activities of $1.6 million as of FY2024, which was up 1,973.68% from $76,000 recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Other financing activities ranged from a high of $1.6 million in FY2024 and a low of $76,000 during FY2023.
  • For the 3-year period, Kymera Therapeutics' Other financing activities averaged around $927,333, with its median value being $1.1 million (2022).
  • Per our database at Business Quant, Kymera Therapeutics' Other financing activities crashed by 93.27% in 2023 and then surged by 1,973.68% in 2024.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Other financing activities stood at $554,000 in 2020, then surged by 53.25% to $849,000 in 2021, then surged by 33.10% to $1.1 million in 2022, then plummeted by 93.27% to $76,000 in 2023, then soared by 1,973.68% to $1.6 million in 2024.